MktsMarkets

SAB Biotherapeutics, Inc.
NASDAQ: SABSKey statistics
SABS News
Stories mentioning SABS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 263.00 | |||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | ||||||||
| Research & Development | 13,398 | 10,728 | 8,970 | 6,997 | 7,657 | 7,453 | 7,831 | 6,822 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 19,998 | 15,770 | 12,679 | 9,732 | 10,772 | 10,124 | 11,309 | 10,465 |
| Operating Income (Loss) | (19,998) | (15,770) | (12,679) | (9,732) | (10,772) | (10,009) | (11,309) | (10,202) |
| Interest Income | ||||||||
| Interest Expense | 93.00 | |||||||
| Other Expense | ||||||||
| Pretax Income | (10,349) | (7,335) | ||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (18,869) | (16,860) | 45,445 | (10,114) | (5,197) | (11,395) | (10,349) | (7,335) |
| Earnings Per Share (Basic) | (0.35) | (0.87) | 0.50 | (1.09) | (0.56) | (1.23) | (1.12) | (0.79) |
| Earnings Per Share (Diluted) | (0.35) | (0.27) | (0.21) | (1.09) | (0.56) | (1.23) | (1.12) | (0.79) |
| Weighted Average Shares Outstanding (Basic) | 53,559 | 19,312 | 10,661 | 9,294 | 9,292 | 9,262 | 9,259 | 9,255 |
| Weighted Average Shares Outstanding (Diluted) | 53,559 | 61,340 | 77,863 | 9,294 | 9,292 | 9,262 | 9,259 | 9,255 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SABS
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a stock listed on the Nasdaq Stock Market under the ticker symbol SABS. It last traded at $2.53 (Oct 16, 2026, 4:00 PM ET), down 2.3% on the day. That gives SAB Biotherapeutics a market capitalisation of $230.2M and a price-to-earnings ratio of 17.3.
Over the past 52 weeks SABS has traded between $2.10 and $5.15.
For the quarter ended Mar 31, 2026 it reported a net loss of $18.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$18.9M |
| Dec 31, 2025 | — | -$16.9M |
| Sep 30, 2025 | — | $45.4M |
| Jun 30, 2025 | — | -$10.1M |
From SAB Biotherapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…